Epigenetic modification of the FMR1 gene in fragile X syndrome is associated with differential response to the mGluR5 antagonist AFQ056. (Q34157712): Difference between revisions

31 July 2017

title

Epigenetic modification of the FMR1 gene in fragile X syndrome is associated with differential response to the mGluR5 antagonist AFQ056. (English)

1 reference

31 July 2017

1 reference

8

Kim Cornish

0 references

Fei Chen

Fei Chen

12

0 references

Feliciano J Ramos

Feliciano J Ramos

7

0 references

Nouchine Hadjikhani

Nouchine Hadjikhani

13

0 references

Jacques S Beckmann

Jacques S Beckmann

16

0 references

Vincent des Portes

3

Vincent des Portes

1 reference

31 July 2017

Sébastien Jacquemont

1

1 reference

31 July 2017

Aurore Curie

2

1 reference

31 July 2017

Maria Giulia Torrioli

4

1 reference

31 July 2017

Elizabeth Berry-Kravis

5

1 reference

31 July 2017

Randi J Hagerman

6

1 reference

31 July 2017

Yunsheng He

9

1 reference

31 July 2017

Charles Paulding

10

1 reference

31 July 2017

Giovanni Neri

11

1 reference

31 July 2017

Danielle Martinet

14

1 reference

31 July 2017

Joanne Meyer

15

1 reference

31 July 2017

Karine Delange

17

1 reference

31 July 2017

Amandine Brun

18

1 reference

31 July 2017

Gerald Bussy

19

1 reference

31 July 2017

Fabrizio Gasparini

20

1 reference

31 July 2017

Talita Hilse

21

1 reference

31 July 2017

Annette Floesser

22

1 reference

31 July 2017

Janice Branson

23

1 reference

31 July 2017

Graeme Bilbe

24

1 reference

31 July 2017

Donald Johns

25

1 reference

31 July 2017

Baltazar Gomez-Mancilla

26

1 reference

31 July 2017

language of work or name

English

0 references

publication date

1 January 2011

1 reference

Science Translational Medicine

31 July 2017

published in

1 reference

31 July 2017

volume

3

1 reference

31 July 2017

issue

64

1 reference

31 July 2017

page(s)

64ra1

1 reference

Advances in the treatment of fragile X syndrome

31 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3001708

Absence of expression of the FMR-1 gene in fragile X syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3001708

Fragile X mental retardation protein replacement restores hippocampal synaptic function in a mouse model of fragile X syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3001708

DNA methylation represses FMR-1 transcription in fragile X syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3001708

The fragile X syndrome protein FMRP associates with BC1 RNA and regulates the translation of specific mRNAs at synapses

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3001708

The mGluR theory of fragile X mental retardation

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3001708

Contribution of mGluR and Fmr1 functional pathways to neurite morphogenesis, craniofacial development and fragile X syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3001708

Fenobam: a clinically validated nonbenzodiazepine anxiolytic is a potent, selective, and noncompetitive mGlu5 receptor antagonist with inverse agonist activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3001708

A pilot open label, single dose trial of fenobam in adults with fragile X syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3001708

Varieties of repetitive behavior in autism: comparisons to mental retardation

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3001708

Transcription of the FMR1 gene in individuals with fragile X syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3001708

Placebo effects in developmental disabilities: implications for research and practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3001708

Comparative analysis of the subcellular and subsynaptic localization of mGluR1a and mGluR5 metabotropic glutamate receptors in the shell and core of the nucleus accumbens in rat and monkey

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3001708

Open-label treatment trial of lithium to target the underlying defect in fragile X syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3001708

10.1126/SCITRANSLMED.3001708

21 January 2018

Identifiers

DOI

1 reference

31 July 2017

1 reference